4/19/2021 8:02:40 AM
Astellas And Seagen Announce FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV
3/26/2021 2:04:54 AM
Astellas Pharma And Seagen: MAA For Enfortumab Vedotin Accepted By European Medicines Agency
3/5/2021 8:03:08 AM
Seagen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Investment
2/18/2021 8:02:16 AM
Astellas And Seagen Submit Two SBLAs To FDA For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer
2/12/2021 6:48:03 AM
Seagen: EC Grants Marketing Authorization For TUKYSA In Combination With Trastuzumab And Capecitabine
2/11/2021 4:07:05 PM
Seagen Q4 EPS $0.90 Vs. $0.14 Year Ago
2/10/2021 4:09:41 PM
Seagen And Genmab A/S Announce Submission Of BLA To FDA Seeking Accelerated Approval For Tisotumab Vedotin
12/11/2020 7:26:15 AM
Seagen Reports Positive CHMP Opinion For TUKYSA For Locally Advanced Or Metastatic HER2-Positive Breast Cancer
12/8/2020 8:07:47 AM
Seagen Announces Presentation Of New Data From TUKYSA At SABCS Symposium
12/7/2020 10:06:16 AM
Seagen Reports Multiple ADCETRIS Presentations At
the 2020 ASH Annual Meeting
11/17/2020 7:56:26 AM
William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
11/9/2020 8:07:15 AM
Seagen Presents Immuno-Oncology Data From Broad Portfolio During SITC Virtual Annual Meeting 2020
11/5/2020 8:13:15 AM
Seagen Announces Multiple ADCETRIS Presentations At Upcoming ASH Annual Meeting